These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

228 related articles for article (PubMed ID: 36059642)

  • 1. Angiogenesis in NENs, with a focus on gastroenteropancreatic NENs: from biology to current and future therapeutic implications.
    Lauricella E; Mandriani B; Cavallo F; Pezzicoli G; Chaoul N; Porta C; Cives M
    Front Oncol; 2022; 12():957068. PubMed ID: 36059642
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Emerging multitarget tyrosine kinase inhibitors in the treatment of neuroendocrine neoplasms.
    Grillo F; Florio T; Ferraù F; Kara E; Fanciulli G; Faggiano A; Colao A;
    Endocr Relat Cancer; 2018 Sep; 25(9):R453-R466. PubMed ID: 29769293
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Genomic Profiles and Current Therapeutic Agents in Neuroendocrine Neoplasms.
    Ohmoto A; Morizane C
    Curr Drug Targets; 2020; 21(4):389-405. PubMed ID: 31633473
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Vascular endothelial growth factor (VEGF) pathway and neuroendocrine neoplasms (NENs): prognostic and therapeutic considerations.
    Abdel-Rahman O
    Tumour Biol; 2014 Nov; 35(11):10615-25. PubMed ID: 25230786
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacodynamics, clinical findings and approval status of current and emerging tyrosine-kinase inhibitors for pancreatic neuroendocrine tumors.
    Fazio N; Cella CA; Del Re M; Laffi A; Rubino M; Zagami P; Spada F
    Expert Opin Drug Metab Toxicol; 2019 Dec; 15(12):993-1004. PubMed ID: 31794273
    [No Abstract]   [Full Text] [Related]  

  • 6. Current treatments and future potential of surufatinib in neuroendocrine tumors (NETs).
    Xu J
    Ther Adv Med Oncol; 2021; 13():17588359211042689. PubMed ID: 34484432
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Emerging Treatment Options for Gastroenteropancreatic Neuroendocrine Tumors.
    Cives M; Pelle' E; Strosberg J
    J Clin Med; 2020 Nov; 9(11):. PubMed ID: 33202931
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immune Checkpoint Inhibitors in the Treatment of Patients with Neuroendocrine Neoplasia.
    Weber MM; Fottner C
    Oncol Res Treat; 2018; 41(5):306-312. PubMed ID: 29742518
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bevacizumab-based combination therapy for advanced gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs): a systematic review of the literature.
    Abdel-Rahman O; Fouad M
    J Cancer Res Clin Oncol; 2015 Feb; 141(2):295-305. PubMed ID: 24990591
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Avelumab in unresectable/metastatic, progressive, grade 2-3 neuroendocrine neoplasms (NENs): Combined results from NET-001 and NET-002 trials.
    Chan DL; Rodriguez-Freixinos V; Doherty M; Wasson K; Iscoe N; Raskin W; Hallet J; Myrehaug S; Law C; Thawer A; Nguyen K; Singh S
    Eur J Cancer; 2022 Jul; 169():74-81. PubMed ID: 35504244
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Update on Epidemiology, Diagnosis, and Biomarkers in Gastroenteropancreatic Neuroendocrine Neoplasms.
    Takayanagi D; Cho H; Machida E; Kawamura A; Takashima A; Wada S; Tsunoda T; Kohno T; Shiraishi K
    Cancers (Basel); 2022 Feb; 14(5):. PubMed ID: 35267427
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Inherited tumor syndromes of gastroenteropancreatic and thoracic neuroendocrine neoplasms].
    Couvelard A; Scoazec JY
    Ann Pathol; 2020 Apr; 40(2):120-133. PubMed ID: 32035641
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tyrosine kinase inhibitors in patients with neuroendocrine neoplasms: a systematic literature review.
    Taboada RG; Cavalher FP; Rego JF; Riechelmann RP
    Ther Adv Med Oncol; 2024; 16():17588359241286751. PubMed ID: 39421680
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinicopathological features and prognosis of gastroenteropancreatic neuroendocrine neoplasms in a Chinese population: a large, retrospective single-centre study.
    Zhang M; Zhao P; Shi X; Zhao A; Zhang L; Zhou L
    BMC Endocr Disord; 2017 Jul; 17(1):39. PubMed ID: 28705205
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Preclinical drug studies in MEN1-related neuroendocrine neoplasms (MEN1-NENs).
    Grozinsky-Glasberg S; Lines KE; Avniel-Polak S; Bountra C; Thakker RV
    Endocr Relat Cancer; 2020 Sep; 27(9):R345-R355. PubMed ID: 32590358
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Role of anti-angiogenesis agents in treating NSCLC: focus on bevacizumab and VEGFR tyrosine kinase inhibitors.
    Cabebe E; Wakelee H
    Curr Treat Options Oncol; 2007 Feb; 8(1):15-27. PubMed ID: 17634832
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Emerging Treatment Options for Neuroendocrine Neoplasms of Unknown Primary Origin: Current Evidence and Future Perspectives.
    Corti F; Rossi RE; Cafaro P; Passarella G; Turla A; Pusceddu S; Coppa J; Oldani S; Guidi A; Longarini R; Cortinovis DL
    Cancers (Basel); 2024 May; 16(11):. PubMed ID: 38893145
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and toxicity of surufatinib in neuroendocrine tumors: A systematic review and meta-analysis.
    Ali MA; Shah SS; Tahir N; Rehman S; Saeed M; Bajwa SF; Ali R; Aiman W; Anwar MY
    J Neuroendocrinol; 2022 Jul; 34(7):e13149. PubMed ID: 35665971
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Therapeutic implication of vascular endothelial growth factor receptor-1 (VEGFR-1) targeting in cancer cells and tumor microenvironment by competitive and non-competitive inhibitors.
    Lacal PM; Graziani G
    Pharmacol Res; 2018 Oct; 136():97-107. PubMed ID: 30170190
    [TBL] [Abstract][Full Text] [Related]  

  • 20. New insights in diagnosis and treatment of gastroenteropancreatic neuroendocrine neoplasms.
    Yin F; Wu ZH; Lai JP
    World J Gastroenterol; 2022 May; 28(17):1751-1767. PubMed ID: 35633912
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.